Relmada Therapeutics, Inc. (OTCQB: RLMD) is a clinical stage, public specialty pharmaceutical company, focused on developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The company has a deep and diversified portfolio of four lead products at different stages of development and an early stage pipeline of an additional four products. Relmada’s product development efforts are guided by the internationally recognized scientific expertise of its research team with inputs from a world-class scientific advisory board. Relmada’s approach is expected to reduce overall clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. SNNLive spoke with Sergio Traversa, CEO of Relmada Therapeutics, Inc. the LD Micro "Main Event" 2014 in Bel Air, CA.
Mr. Traversa begins the interview with an overview of the company, “Relmada Therapeutics is a publicly-traded pharma/biotechnology company that develops pain medication. The ticker symbol is RLMD and it was founded in 2004, but restarted operation technically when I joined the company in mid-2012 when we raised the first $3 million in private placement and subsequently from then to now the company has evolved dramatically, and we are fully stocked with executives in each function, we raised a total of $53 million, of which, $43 million through a public transaction this year, and what we do is we develop pain medication for the treatment of patients that are affected by pain.”
He continues with why Relmada is focused on pain medications, “It is the largest prescription market in the world, it’s highly unsatisfied, only 1 out of 4 patients says that the pain medication he’s taking is taking his pain away, creates a lot of monetized damages for days lost of work and there is a big need for new pain medication. On top of that, there is a secondary issue that has been very evident in the last few years, that is abuse, so what we do is we develop pain medication that we believe are better and safer and more effective than the one available, but also much less easy to abuse.”
He discusses the current stages of the treatments, “We have 4 programs so they are at different stages of development, the most advanced is LevoCap ER that we believe it will enter phase III in the second half of next year, the second is d-Methadone that we believe will enter phase II also in the second half of next year. The other two, they are at the formulation right now, we expect the clinical trials to start first quarter of next year but because it’s a very short trial, we expect clinical results in the second quarter of next year.” For more information, check out their website: www.Relmada.com
© 2017 Stock News Now
Supported by Superior Web Solutions